6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
7m ago	Workday Government Unveils Personnel Action Request (PAR) Agent to Modernize Federal HR and Strengthen Mission Readiness
8m ago	CNOOC Limited Achieves Strong Start with Dual Growth in Production and Performance in Q1 2026
9m ago	onsemi and Geely Expand Strategic Collaboration to Elevate the Driving Experience
10m ago	Myriad Uranium Appoints Eric Miller as Strategic Advisor on US Critical Minerals
42m ago	UPDATED NOTICE REGARDING THE PROPOSED AMENDMENT TO THE PRINCIPAL AMOUNT OF THE AFFECTED SECURITIES ADJOURNMENT OF MEETING OF THE ETP SECURITYHOLDERS

About

Myriad Genetics Inc (NASDAQ:MYGN) — investor relations, events, news, and company updates on 6ix.

Latest News

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Financials

Revenue

$557 M

Market Cap

$444.16 M

EPS

-3.95

Community Chat

Ask AI